BiotechTube
Home/DalCor Pharmaceuticals/Michael Dixon, C.P.A., C.A.
MD

Michael Dixon, C.P.A., C.A.

Chief Financial Officer

DalCor Pharmaceuticals

Therapeutic Areas

Cardiovascular

DalCor Pharmaceuticals Pipeline

DrugIndicationPhase
dalcetrapibReduction of recurrent myocardial infarction in post-acute coronary syndrome (ACS) patients with ADCY9 AA genotypePhase 3

Leadership Team at DalCor Pharmaceuticals

FL
Fouzia Laghrissi-Thode, M.D.
Chief Executive Officer
View full DalCor Pharmaceuticals profile